Sidharth Puram

Dr. Sidharth Puram

Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, 4921 Parkview Pl, St. Louis, MO 63110, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Nature
Verified
Journal Article
Closed access
PDF file
AGAvishai Gavish
Avishai Gavish
MTMichael Tyler
Michael Tyler
AGAlissa C. Greenwald
Alissa C. Greenwald
RHRouven Hoefflin
Rouven Hoefflin
DSDor Simkin
Dor Simkin
ITItay Tirosh
Itay Tirosh

7 February 2008 in Genes & Development
Verified
Journal Article
Closed access
PDF file
NINúria de la Iglesia
Núria de la Iglesia
GKGenevieve Konopka
Genevieve Konopka
Sidharth PuramSidharth Puram
Sidharth Puram
JCJennifer A. Chan
Jennifer A. Chan
RBRobert M. Bachoo
Robert M. Bachoo
ABAzad Bonni
Azad Bonni
Activation of the transcription factor STAT3 is thought to potently promote oncogenesis in a variety of tissues, leading to intense efforts to develop STAT3 inhibitors for many tumors, including the highly malignant brain tumor glioblastoma. However, the function of STAT3 in glioblastoma pathogenesis has remained unknown. Here, we report that STAT3 plays a pro-oncogenic or tumor-suppressive role depending on the mutational profile of the tumor. Deficiency of the tumor suppressor PTEN triggers a cascade that inhibits STAT3 signaling in murine astrocytes and human glioblastoma tumors. Specifically, we forge a direct link between the PTEN–Akt–FOXO axis and the leukemia inhibitory factor receptor β (LIFRβ)–STAT3 signaling pathway. Accordingly, PTEN knockdown induces efficient malignant transformation of astrocytes upon knockout of the STAT3 gene. Remarkably, in contrast to the tumor-suppressive function of STAT3 in the PTEN pathway, STAT3 forms a complex with the oncoprotein epidermal growth factor receptor type III variant (EGFRvIII) in the nucleus and thereby mediates EGFRvIII-induced glial transformation. These findings indicate that STAT3 plays opposing roles in glial transformation depending on the genetic background of the tumor, providing the rationale for tailored therapeutic intervention in glioblastoma.

1 November 2023 in Nature
Verified
Journal Article
Open access
PDF file
NTNadezhda V. Terekhanova
Nadezhda V. Terekhanova
AKAlla Karpova
Alla Karpova
WLWen-Wei Liang
Wen-Wei Liang
ASAlexander Strzalkowski
Alexander Strzalkowski
SCSiqi Chen
Siqi Chen
LDLi Ding
Li Ding
Chromatin accessibility is essential in regulating gene expression and cellular identity, and alterations in accessibility have been implicated in driving cancer initiation, progression and metastasis1–4. Although the genetic contributions to oncogenic transitions have been investigated, epigenetic drivers remain less understood. Here we constructed a pan-cancer epigenetic and transcriptomic atlas using single-nucleus chromatin accessibility data (using single-nucleus assay for transposase-accessible chromatin) from 225 samples and matched single-cell or single-nucleus RNA-sequencing expression data from 206 samples. With over 1 million cells from each platform analysed through the enrichment of accessible chromatin regions, transcription factor motifs and regulons, we identified epigenetic drivers associated with cancer transitions. Some epigenetic drivers appeared in multiple cancers (for example, regulatory regions of ABCC1 and VEGFA; GATA6 and FOX-family motifs), whereas others were cancer specific (for example, regulatory regions of FGF19, ASAP2 and EN1, and the PBX3 motif). Among epigenetically altered pathways, TP53, hypoxia and TNF signalling were linked to cancer initiation, whereas oestrogen response, epithelial–mesenchymal transition and apical junction were tied to metastatic transition. Furthermore, we revealed a marked correlation between enhancer accessibility and gene expression and uncovered cooperation between epigenetic and genetic drivers. This atlas provides a foundation for further investigation of epigenetic dynamics in cancer transitions.

30 October 2024 in Nature
Verified
Journal Article
Open access
PDF file
CMChia-Kuei Mo
Chia-Kuei Mo
JLJingxian Liu
Jingxian Liu
SCSiqi Chen
Siqi Chen
ESErik Storrs
Erik Storrs
ACAndre Luiz N. Targino da Costa
Andre Luiz N. Targino da Costa
LDLi Ding
Li Ding
To study the spatial interactions among cancer and non-cancer cells1, we here examined a cohort of 131 tumour sections from 78 cases across 6 cancer types by Visium spatial transcriptomics (ST). This was combined with 48 matched single-nucleus RNA sequencing samples and 22 matched co-detection by indexing (CODEX) samples. To describe tumour structures and habitats, we defined ‘tumour microregions’ as spatially distinct cancer cell clusters separated by stromal components. They varied in size and density among cancer types, with the largest microregions observed in metastatic samples. We further grouped microregions with shared genetic alterations into ‘spatial subclones’. Thirty five tumour sections exhibited subclonal structures. Spatial subclones with distinct copy number variations and mutations displayed differential oncogenic activities. We identified increased metabolic activity at the centre and increased antigen presentation along the leading edges of microregions. We also observed variable T cell infiltrations within microregions and macrophages predominantly residing at tumour boundaries. We reconstructed 3D tumour structures by co-registering 48 serial ST sections from 16 samples, which provided insights into the spatial organization and heterogeneity of tumours. Additionally, using an unsupervised deep-learning algorithm and integrating ST and CODEX data, we identified both immune hot and cold neighbourhoods and enhanced immune exhaustion markers surrounding the 3D subclones. These findings contribute to the understanding of spatial tumour evolution through interactions with the local microenvironment in 2D and 3D space, providing valuable insights into tumour biology.

1 January 2009 in Cell
Verified
Journal Article
Closed access
AKAlbert H. Kim
Albert H. Kim
Sidharth PuramSidharth Puram
Sidharth Puram
PBParizad M. Bilimoria
Parizad M. Bilimoria
YIYoshiho Ikeuchi
Yoshiho Ikeuchi
SKSamantha Keough
Samantha Keough
ABAzad Bonni
Azad Bonni

8 July 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
APAnanya Pal
Ananya Pal
TBThomas F. Barrett
Thomas F. Barrett
RPRachel Paolini
Rachel Paolini
APAnuraag Parikh
Anuraag Parikh
Sidharth PuramSidharth Puram
Sidharth Puram